ArticleNAM journal2026

Impact of the FDA roadmap and perspectives for regulatory use of new approach methodologies in Japanese pharmaceutical companies.

Tetsuro Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.